Clinical and Genetic Studies on Holoprosencephaly
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00088426 |
|
Recruitment Status :
Completed
First Posted : July 26, 2004
Last Update Posted : April 20, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study will examine how holoprosencephaly (HPE) affects people, how they change over time, and what genes may be involved in the cause of the disorder. HPE is a defect of brain development in utero in which the forebrain fails to sufficiently divide into two hemispheres, resulting in a single-lobed brain and skull and facial malformations. In most cases, the defects are so severe that babies die before birth. There are three classifications of HPE. In alobar HPE the brain does not divide at all; this form is usually associated with severe facial deformities. In semilobar HPE the hemispheres divide somewhat, causing an intermediate form of the disorder. In lobar HPE, the mildest form, separation of hemispheres is nearly normal.
Patients with HPE and their direct blood relatives may participate in this study. Patients are seen by a team of medical specialists at the NIH Clinical Center for the following procedures:
- Physical and neurological examination
- Eye examination
- Imaging studies, such as echocardiogram, abdominal ultrasound, brain MRI
- Electroencephalogram (EEG)
- Hearing evaluation
- Blood and urine samples for genetic and endocrine studies, routine blood chemistries, urinalysis, and urine electrolytes
- Other consultations as needed
- Possibly photographs, including front and side views of the face and other body parts that may be involved in HPE, such as the eyes, teeth, hands, and feet
Parents will be asked questions about the child's prenatal, birth, newborn, and past medical history, growth, behavior and development, and therapy and medication.
Because HPE is a genetic disorder and gene changes can be passed on in a family, parents will also be asked to undergo the following procedures:
- Completion of a medical and family history form
- Physical and neurological examination
- Blood and urine samples (for mothers only)
- Specialty consultations as indicated
- Possibly photographs, including front and side views of the face and other body parts that may be involved in HPE, such as the eyes, teeth, hands, and feet
- Psychosocial study. Some parents will be asked to participate in a telephone interview or complete a questionnaire, or both, about their attitudes, beliefs, and concerns about how they and their family cope with their child's condition. Some questionnaires may include questions about aspects of their marriage and personal feelings and experiences.
Parents will meet with a doctor and a genetics nurse to discuss the results of the tests and answer questions. Parents may be asked to bring their child back to the NIH after 2 years for follow-up examination and possible additional or repeat testing.
...
| Condition or disease |
|---|
| Holoprosencephaly HPE Developmental Delay Disorders Brain Disorders |
| Study Type : | Observational |
| Actual Enrollment : | 256 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Prospective |
| Official Title: | Clinical and Genetic Studies on Holoprosencephaly |
| Actual Study Start Date : | January 23, 2004 |
| Actual Primary Completion Date : | March 16, 2020 |
| Actual Study Completion Date : | April 16, 2020 |
| Group/Cohort |
|---|
|
Control
Control group of Williams-Beuren (also known as Williams) syndrome
|
|
Family
Direct blood relatives (typically parents, and occasionally siblings of affected individuals) ofpatients with HPE are also eligible to participate.
|
|
HPE
Patients with HPE
|
- To characterize the physical, developmental, neurologic, endocrinologic and radiologic phenotype of HPE through this comprehensive natural history study. [ Time Frame: Once with possible followup at Year 2 ]To characterize the physical, developmental, neurologic, endocrinologic and radiologic phenotype of HPE through this comprehensive natural history study.
- To examine the spectrum of clinical characteristics of HPE and facilitate early clinical recognition, diagnostic confirmation, anticipatory management, prognostication, and proper genetic counseling. [ Time Frame: Once with possible followup at Year 2 ](a) To compare gene mutations (with known or suspected abnormal functional effects) with the phenotypes observed in patients (i.e genotype-phenotype correlations) as documented in the study. (b) To determine the spectrum of brain malformations caused by genetic changes in HPE candidate genes that are known or suspected to cause human disease. (c) To correlate neurodevelopmental status/clinical outcome with neuroradiologic findings and genetic changes in HPE candidate genes. (d) To verify recurrence risks /inheritance patterns of HPE for each of the HPE candidate genes.
- To determine the spectrum of non-neurologic anomalies resulting from mutations in HPE-associated genes /pathways both in individuals with HPE and individuals without HPE. [ Time Frame: Once with possible followup at Year 2 ](a) To determine the association between mutations in HPE-associated genes/pathways and the non- neurologic finding of fatty liver in individuals with HPE. (b) To determine the presence of other, previously unknown clinical manifestations in individuals with HPE.
- To assess the psychosocial impact of HPE on the family system. [ Time Frame: Once with possible followup at Year 2 ](a) To describe characteristics of stress and coping in families of children affected by HPE. (b) To examine the relationships between specific child characteristics (e.g., chronological age, severity of disorder), family coping styles and family variables (e.g., stress, coping, marital satisfaction, parental anxiety and depression).(c) To examine the similarities and/or differences between mothers and fathers experiences of stress and coping in families of children with HPE. (d) To generate data for the development of a new instrument to quantify stress, coping and resilience in HPE families.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 1 Month and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
-
INCLUSION CRITERIA:
- Depending on their willingness to participate, subjects may enroll in DNA laboratory-only (98-HG-0249), psychosocial-only, or clinical-only. However, to conserve resources and meet study objectives, subjects with known mutations will be given priority in selection for extensive clinical studies. All races and genders are known to be at risk for HPE, anywhere in the world. Nationality or place of origin is not specific barrier to participation.
- Direct blood relatives (typically parents, and occasionally siblings of affected individuals) of patients with HPE are also eligible to participate.
EXCLUSION CRITERIA:
- Anyone unwilling to provide informed consent (for themselves as adults, or on behalf of their children as minors) or assent.
- Medical condition(s) or mental retardation are not in themselves reason for exclusion if in the judgment of the referring physician this would involve no more than minimal risk. We anticipate that children with mental handicaps would be included in the research population. We will make every effort to explain the study for the purpose of assent in a manner that the family feels is both age and developmentally appropriate for that child.
- We generally review a brief clinical description from the referring physician about a potential research subject to determine that the subject is appropriate to enter into the study. We reserve the right to exclude cases that are clearly not HPE or related to our direct research interests (e.g. HPE cases that are syndromic like Smith Lemli Opitz syndrome, Trisomy 13, Trisomy 18, drug-related, or teratogen-related). This almost never happens, and we would attempt to make referrals to a more appropriate investigator.
It is our intention to try to remove as many economic, cultural, geographic, racial, and gender barriers as we reasonably can to promote participation of HPE cases for research purposes.
Description and justification of clinical inclusion/exclusion criteria for environmental study arm control group (individuals with Williams syndrome) :
Participants must have a confirmed diagnosis of Williams syndrome caused by deletions in chromosome 7q11 involving the Williams-Beuren Syndrome Critical Region (WBSCR). Children should be less than 6 years of age to allow for improved maternal recall of prenatal
environmental exposures. The Williams syndrome cohort (PI: Dr. Beth Kozel; National Heart Lung Blood Institute) was chosen to allow for inherent biases in mothers who have children with multiple anomaly syndromes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00088426
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | |
| Bethesda, Maryland, United States, 20892 | |
| Principal Investigator: | Paul S Kruszka, M.D. | National Human Genome Research Institute (NHGRI) |
Publications:
| Responsible Party: | National Human Genome Research Institute (NHGRI) |
| ClinicalTrials.gov Identifier: | NCT00088426 |
| Other Study ID Numbers: |
040093 04-HG-0093 |
| First Posted: | July 26, 2004 Key Record Dates |
| Last Update Posted: | April 20, 2020 |
| Last Verified: | April 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
GENETIC DISEASE Multiple Abnormalies Birth Defects Holoprosencephaly HPE |
|
Holoprosencephaly Brain Diseases Disease Developmental Disabilities Pathologic Processes Central Nervous System Diseases Nervous System Diseases Neurodevelopmental Disorders Mental Disorders |
Craniofacial Abnormalities Musculoskeletal Abnormalities Musculoskeletal Diseases Agenesis of Corpus Callosum Nervous System Malformations Abnormalities, Multiple Congenital Abnormalities Chromosome Disorders Genetic Diseases, Inborn |